论文部分内容阅读
分组:益肝灵组40例,安妥明对照组30例。两组患者均无粘液性水肿,肾病综合征,胰腺炎或肝胆疾患。方法:治疗组口服益肝灵,每次2～3片,每天三次。对照组口服安妥明,每次250mg,每日三次。均以二周为一疗程,治疗期间均进普通饮食,未加用其它降脂药物。疗效:服药一疗程后复查血脂下降20mg％以上者为有效,否则属无效。治疗一疗程后抽查部分病例血脂下降情况:益肝灵组胆固醇下降30例,有效者占76.7％,甘油三酯下降34例,有效者占85.2％。安妥明组胆固醇下降17例,有效者占41.3％。甘油三酯下降27例有效者占70.4％,治疗前后胆固醇平均值,益肝
Grouping: Yiganling group 40 cases, 30 cases of control group. Two groups of patients were no myxedema, nephrotic syndrome, pancreatitis or hepatobiliary disease. Methods: The treatment group oral Yigan, each 2 to 3 tablets three times a day. Control group oral clofibrate, each 250mg, three times a day. Two weeks for a course of treatment, both during the regular diet, not with other lipid-lowering drugs. Efficacy: medication after a review of blood lipids decreased more than 20mg% effective, otherwise invalid. After a course of treatment, the blood samples of some cases were dectected. The serum cholesterol decreased in 30 cases of Yiganling group, accounting for 76.7% of the patients in the Yiganling group, 34 cases of decrease in triglycerides, and 85.2% of the patients in the Yiganling group. In the statin group, cholesterol decreased by 17% and effective rate was 41.3%. 27 cases of triglyceride decreased effective accounted for 70.4%, before and after treatment, the average cholesterol, liver